Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alfuzosin Hydrochloride

FDA-approved product (tablet, extended release, oral), marketed as Alfuzosin Hydrochloride, Uroxatral.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alfuzosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alfuzosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alfuzosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

    NCT00713739 · start 2008-01

    Registered record
    Registry ID
    NCT00713739
    Conditions
    Kidney Stones
    Interventions
    Alfuzosin; nifedipine; doxazosin; prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-01
    Completion
    2012-12
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    InterventionAlfuzosin; nifedipine; doxazosin; prazosin
    PhasePhase 3
    Registry statusUnknown

  • Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

    NCT00576823 · start 2007-12

    Registered record
    Registry ID
    NCT00576823
    Conditions
    Hydronephrosis; Neurogenic Bladder
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2009-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHydronephrosis; Neurogenic Bladder
    InterventionAlfuzosin
    PhasePhase 3
    Registry statusCompleted

  • Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)

    NCT00688948 · start 2007-11

    Registered record
    Registry ID
    NCT00688948
    Conditions
    Multiple Sclerosis; Bladder Dysfunction
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2009-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Bladder Dysfunction
    InterventionAlfuzosin
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

    NCT00549939 · start 2007-10

    Registered record
    Registry ID
    NCT00549939
    Conditions
    Neurogenic Urinary Bladder
    Interventions
    Alfuzosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-12
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurogenic Urinary Bladder
    InterventionAlfuzosin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones

    NCT00583258 · start 2007-10

    Registered record
    Registry ID
    NCT00583258
    Conditions
    Kidney Stones
    Interventions
    Alfuzosin (Xatral); Placebo Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2007-10
    Completion
    2009-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    InterventionAlfuzosin (Xatral); Placebo Alfuzosin
    PhaseNot applicable
    Registry statusWithdrawn

  • The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

    NCT00451061 · start 2007-04

    Registered record
    Registry ID
    NCT00451061
    Conditions
    Renal Colic
    Interventions
    Alfuzosin; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-04
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Colic
    InterventionAlfuzosin; Tamsulosin
    PhasePhase 4
    Registry statusUnknown

  • Comparative Treatment Study in Patients With Lower Ureteral Stones

    NCT00397397 · start 2007-01

    Registered record
    Registry ID
    NCT00397397
    Conditions
    Urinary Calculi
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2007-01
    Completion
    2007-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Calculi
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia

    NCT00399464 · start 2006-11

    Registered record
    Registry ID
    NCT00399464
    Conditions
    Prostatic Hyperplasia
    Interventions
    alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-10
    Enrolment
    1,177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Interventionalfuzosin
    PhasePhase 3
    Registry statusCompleted

  • Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study

    NCT00427882 · start 2006-09

    Registered record
    Registry ID
    NCT00427882
    Conditions
    Prostatic Hyperplasia
    Interventions
    ALFUZOSIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-05
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionALFUZOSIN
    PhasePhase 4
    Registry statusCompleted

  • Benign Prostatic Hyperplasia in Taiwan

    NCT00941343 · start 2006-09

    Registered record
    Registry ID
    NCT00941343
    Conditions
    Prostatic Diseases
    Interventions
    Alfuzosin (XATRAL® - SL770499)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-09
    Completion
    2008-09
    Enrolment
    362

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Diseases
    InterventionAlfuzosin (XATRAL® - SL770499)
    PhaseNot applicable
    Registry statusCompleted

  • ALF-STONE: Alfuzosin in Uretheric Stones

    NCT00454402 · start 2006-08

    Registered record
    Registry ID
    NCT00454402
    Conditions
    Prostatic Hyperplasia
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-08
    Completion
    2007-07
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionAlfuzosin
    PhasePhase 3
    Registry statusTerminated

  • Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology

    NCT00629720 · start 2006-07

    Registered record
    Registry ID
    NCT00629720
    Conditions
    Urinary Bladder Neurogenic
    Interventions
    alfuzosin (SL770499)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-02
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Neurogenic
    Interventionalfuzosin (SL770499)
    PhasePhase 3
    Registry statusCompleted

  • Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

    NCT00401661 · start 2006-06

    Registered record
    Registry ID
    NCT00401661
    Conditions
    Prostatic Hyperplasia
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

    NCT00467467 · start 2006-06

    Registered record
    Registry ID
    NCT00467467
    Conditions
    Ureteral Stent Discomfort
    Interventions
    Alfuzosin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Stent Discomfort
    InterventionAlfuzosin Hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

    NCT00347061 · start 2006-05

    Registered record
    Registry ID
    NCT00347061
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    afuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-10
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionafuzosin
    PhasePhase 3
    Registry statusCompleted